Related Experiment Video
Updated: Jun 2, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Should we consider MMF therapy after rituximab for nephrotic syndrome?
Guido Filler1, Shih-Han Susan Huang, Ajay P Sharma
1Department of Pediatrics, Schulich School of Medicine & Dentistry, London, ON, Canada, N6A 5W9. guido.filler@lhsc.on.ca
Abstract:
The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome I : Introduction
Myocarditis III: Medical Management
Rocky Mountain Spotted Fever
